Casting-type calcifications on the mammogram suggest a higher probability of early relapse and death among high-risk breast cancer patients
暂无分享,去创建一个
Krisztina Boda | K. Boda | K. Ormándi | István Pálka | Katalin Ormándi | Szilvia Gaál | Zsuzsanna Kahán | Z. Kahán | I. Pálka | Szilvia Gaál
[1] K. Shen,et al. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .
[2] I. Ellis,et al. Is the presence of mammographic comedo calcification really a prognostic factor for small screen-detected invasive breast cancers? , 2003, Clinical radiology.
[3] J. O’Shaughnessy. Extending survival with chemotherapy in metastatic breast cancer. , 2005, The oncologist.
[4] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[5] L. Tabár,et al. A new era in the diagnosis of breast cancer. , 2000, Surgical oncology clinics of North America.
[6] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[7] B. Cady,et al. Casting-type calcifications with invasion and high-grade ductal carcinoma in situ: a more aggressive disease? , 2003, Archives of surgery.
[8] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[9] John R. Mackey,et al. Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. , 2009 .
[10] M. Eisenberger,et al. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. , 2005, The oncologist.
[11] R. Given-Wilson,et al. Mammographic casting-type calcification associated with small screen-detected invasive breast cancers: is this a reliable prognostic indicator? , 2004, Clinical radiology.
[12] Yueh-Hsia Chiu,et al. Mammographic tumor features can predict long‐term outcomes reliably in women with 1–14‐mm invasive breast carcinoma , 2004, Cancer.
[13] A. Purushotham,et al. Predicting local recurrence by correlating pre-operative mammographic findings with pathological risk factors in patients with breast cancer. , 1995, The British journal of radiology.
[14] Philip Smith,et al. Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component. , 1994, Seminars in diagnostic pathology.
[15] A. Purushotham,et al. Preoperative mammographic features predict clinicopathological risk factors for the development of local recurrence in breast cancer. , 2000, Breast.
[16] K. Byth,et al. Histopathologic indicators of breast cancer biology: insights from population mammographic screening , 2005, British Journal of Cancer.
[17] 青儀 健二郎,et al. What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及 , 2006 .
[18] E. Thurfjell,et al. Mammographic finding as predictor of survival in 1–9mm invasive breast cancers. Worse prognosis for cases presenting as calcifications alone , 2001, Breast Cancer Research and Treatment.
[19] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[20] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[21] M. V. Vijver. Gene-Expression Profiling and the Future of Adjuvant Therapy , 2005 .
[22] K. Boda,et al. Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy Is Well Tolerated and Safe in High-Risk Early Breast Cancer , 2005, Oncology.
[23] I. Fentiman,et al. Ductal in situ Component and Prognosis in Invasive Mammary Carcinoma , 2004, Breast Cancer Research and Treatment.
[24] Stephen W Duffy,et al. A novel method for prediction of long-term outcome of women with T1a, T1b, and 10–14 mm invasive breast cancers: a prospective study , 2000, The Lancet.
[25] P. Ravdin,et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.